BDSX (Biodesix) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDSX Biodesix Inc BDSX
53 GF Score
Price $22.34
GF Value $21.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Biodesix Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

BDSX
53GF Score
Biodesix Inc BDSX
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biodesix (BDSX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodesix stock appears to be overvalued. The current stock price of $22.34 is trading 4.7% above its estimated GF Value™ of $21.33. GuruFocus considers Biodesix to be Fairly Valued.

Key valuation signals for BDSX:

  • Cash Payments:
  • GF Value™: $21.33 vs. price of $22.34 (4.7% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodesix Business Description

Address 919 West Dillon Road, Louisville, CO, USA, 80027
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
53GF Score

Get the complete analysis for BDSX

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.34
Price
$21.33
GF Value